Kheir, Alaa, et al. “Baseline Laboratory Values and Metastatic Burden Predict Survival in Addition to IMDC Risk in Real-World Renal Cell Carcinoma Patients Treated With Ipilimumab-Nivolumab”. Acta Oncologica, vol. 64, Oct. 2025, pp. 1355-64, doi:10.2340/1651-226X.2025.44533.